Want to join the conversation?
$CELG said its cancer drug received approval to treat patients with newly diagnosed multiple myeloma in Japan. The approval was based on safety and efficacy results from an international phase 3 study, the FIRST trial as the pivotal study, as well as a confirmatory Japanese phase 2 study. This expands upon approval of REVLIMID in 2010.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.